DOCSLIB.ORG

SECTION 1: History and Scope of the Pharmacy Technician

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
SECTION 1: History and Scope of the Pharmacy Technician SECTION 1: History and Scope of the Pharmacy Technician Scope of the Pharmacy Technician Section 1 Quiz — Check Your Knowledge Section 1 — Quiz Answers SECTION 2: Manufacturing Pharmaceuticals Section 2 Quiz — Check Your Knowledge Section 2 — Quiz Answers SECTION 3: Rules and Regulations (PTCB 2.0) Omnibus Budget Reconciliation Act of 1990 (OBRA ’90)(PTCB 2.9) Poison Prevention Packaging Act of 1970 (PPPA) Health Insurance Portability and Accountability Act (HIPAA) (PTCB 2.8) Combat Methamphetamine Epidemic Act of 2005 (CMEA) Manufacturer Drug Package Labeling Repackaging Medications (PTCB 2.12) Therapeutic Equivalence (PTCB 1.2) Section 3 Quiz — Check Your Knowledge Section 3 – Quiz Answers SECTION 4: Controlled Substances (PTCB 2.4) Schedule for Controlled Substances Forms Required for Storing, Maintaining and Distributing Controlled Substances(PTCB 2.3, 2.4) Storage and Record Keeping for Controlled Substances Prescribing and Filling Rules and Regulations for Controlled Substances Prescribing Rules for Schedule C-III to C-V Medications for Treatment of Addiction (buprenorphine) Validating Prescribers Section 4 Quiz — Check Your Knowledge Section 4 – Quiz Answers SECTION 5: Pharmacy Safety Storage and Handling of Hazardous Substances (PTCB 2.1, 2.2) Hazardous Drugs – Drugs That Can Have Very High Risk Side Effects Restricted Drug Programs(PTCB 2.7) Frequently Used REMS System for Thalidomide Education and Prescribing Safety Medication Safety (PTCB 4.3) Look Alike – Sound Alike Medications (PTCB 4.4) Common Drug Interactions (PTCB 1.3) Drug – Drug Interactions Drug – Food Interactions Drug – Disease Interaction Section 5 Quiz — Check Your Knowledge Section 5 – Quiz Answers SECTION 6: Drug Classifications (PTCB Pharmacology 1.1 – 1.6) Drugs For the Treatment of Hypertension Angiotensin Converting Enzyme (ACE) Inhibitors Angiotensin Receptor Blockers (ARB) Thiazide Diuretics and Loop Diuretics Potassium Sparing Diuretics Alpha1 Blockers (Antagonist – Blocks the Receptor) Alpha2 Receptor Agonist (Activates the Receptor) Beta Blockers (Antagonist – Blocks the Receptor) Calcium Channel Blockers Drugs Used to Treat Cholesterol HMG-CoA Reductase Inhibitors (Statins) Drugs Used to Treat Diabetes Insulin Biguanides Dipeptidyl Peptidase-4 Inhibitors Sulfonylureas GLP-1 Agonist (Activates the Receptor) Drugs Used to Treat Heart Conditions Vasodilators (Make Blood Vessels Larger) Antiarrhythmics (For Cardiac Arrhythmias) Drugs Used to Prevent or Treat Blood Clots Anticoagulants Antiplatelet Medications Medications Used to Treat Psychiatric Disorders Selective Serotonin Reuptake Inhibitors (SSRI) Serotonin-Norepinephrine Reuptake Inhibitors (SNRI) Drug Forms (PTCB 1.4) Release of Medications into the Body Liquid Dosage Forms Medication Labelling Section 6 Quiz — Check Your Knowledge Section 6 – Quiz Answers SECTION 7: Sterile and Non-Sterile Compounding (PTCB 3.0 – 3.7) Equipment Used in Compounding (PTCB 3.5) Electronic Pharmacy Balance Class A Prescription Balance Alligation Sterile Compounding (PTCB 3.6) United States Pharmacopeia (USP) Chapter 797 Beyond Use Date (BUD) (PTCB 3.4) The International Organization for Standardization (ISO) Common Abbreviations Used in a Clean Room Non-Sterile Compounding (PTCB 3.7) Common Abbreviations Used in Compounding Section 7 Quiz — Test Your Knowledge Section 7 – Quiz Answers SECTION 8: Pharmacy Quality Assurance (PTCB 5.1-5.5) Recalls Medication Order Entry and Fill Process (PTCB 6.1 – 6.7) Medication Dosing Administration Routes Units of Measure Section 8 Quiz — Check Your Knowledge Section 8 — Quiz Answers SECTION 9 – Mathematics in Pharmacy (PTCB 3.6, 6.3) Fractions – The Basics Common Denominator Reducing Fractions Adding Fractions Subtracting Fractions Multiply Fractions Divide Fractions Converting Fractions To Decimals Percentages To Fractions Fractions Converted To Percent Practical Application Avoirdupois System (United States) The Metric System – Standard System of Measure for Medicine (and Pharmacy) Roman Numerals Calculating Averages Section 9 Quiz — Check Your Knowledge Section 9 – Quiz Answers SECTION 10: Inventory Management (PTCB 7.1-7.5) National Drug Code Number (NDC) Maintaining Inventory Maintaining a Safe Inventory Rotating Stock Storing Medications Safely Section 10 Quiz — Test Your Knowledge Section 10 – Quiz Answers SECTION 11: Pharmacy Billing and Reimbursement (PTCB 8.0) Different Types of Insurance Companies Section 11 Quiz — Check Your Knowledge Section 11 – Quiz Answers SECTION 12: Information Systems (PTCB 9.0) Bibliography Appendix A Alphabetically by Brand Name Alphabetically by Generic Name Appendix B Categories of Medications and their Purpose Appendix C Common Medications by Categories Alphabetically by Brand Name Alphabetically by Drug Category Alphabetically by Generic Name.
Load more

Recommended publications
  • Commentary USP 40–NF 35
    Commentary USP 40–NF 35 November 1, 2016 In accordance with USP’s Rules and Procedures of the Council of Experts (“Rules”) and except as provided in Section 7.02 Accelerated Revision Processes, USP publishes proposed revisions to the United States Pharmacopeia and the National Formulary (USP–NF) for public review and comment in the Pharmacopeial Forum (PF), USP’s free bimonthly journal for public notice and comment. After comments are considered and incorporated as the Expert Committee deems appropriate, the proposal may advance to official status or be re-published in PF for further notice and comment, in accordance with the Rules. In cases when proposals advance to official status without re-publication in PF, a summary of comments received and the appropriate Expert Committee's responses are published in the Revisions and Commentary section of the USP website at the time the official revision is published. The Commentary is not part of the official text and is not intended to be enforceable by regulatory authorities. Rather, it explains the basis of Expert Committees’ responses to public comments on proposed revisions. If there is a difference between the contents of the Commentary and the official text, the official text prevails. In case of a dispute or question of interpretation, the language of the official text, alone and independent of the Commentary, shall prevail. For further information, contact: USP Executive Secretariat United States Pharmacopeia 12601 Twinbrook Parkway Rockville, MD 20852-1790 USA [email protected] Page 1
    [Show full text]
  • Oxford® Policy Update Bulletin: October 2015 Oxford
    Oxford October 2015 policy update bulletin Medical & Administrative Policy Updates UnitedHealthcare respects the expertise of the physicians, health care professionals, and their staff who participate in our network. Our goal is to support you and your patients in making the most informed decisions regarding the choice of quality and cost-effective care, and to support practice staff with a simple and predictable administrative experience. The Policy Update Bulletin was developed to share important information regarding Oxford® Medical and Administrative Policy updates.* *Where information in this bulletin conflicts with applicable state and/or federal law, Oxford® follows such applicable federal and/or state law Oxford Oxford® Medical and Administrative Policy Updates Overview This bulletin provides complete details on Oxford® Medical and Policy Update Classifications Administrative Policy updates. The appearance of a service or New procedure in this bulletin indicates only that Oxford® has recently New clinical coverage criteria and/or documentation review requirements adopted a new policy and/or updated, revised, replaced or have been adopted for a service, procedure, test, or device retired an existing policy; it does not imply that Oxford® provides Updated coverage for the service or procedure. In the event of an An existing policy has been reviewed and changes have not been made inconsistency or conflict between the information provided in this to the clinical coverage criteria or documentation review requirements; bulletin and the posted policy, the provisions of the posted policy however, items such as the clinical evidence, FDA information, and/or will prevail. Note that most benefit plan documents exclude from list(s) of applicable codes may have been updated benefit coverage health services identified as investigational or unproven/not medically necessary.
    [Show full text]
  • UNITED STATES SECURITIES and EXCHANGE COMMISSION Washington, D.C
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report For the transition period from to Commission File Number: 1-15182 DR. REDDY’S LABORATORIES LIMITED (Exact name of Registrant as specified in its charter) Not Applicable TELANGANA, INDIA (Translation of Registrant’s name (Jurisdiction of incorporation or into English) organization) 8-2-337, Road No. 3, Banjara Hills Hyderabad, Telangana 500 034, India +91-40-49002900 (Address of principal executive offices) Saumen Chakraborty, Chief Financial Officer, +91-40-49002004, [email protected] 8-2-337, Road No. 3, Banjara Hills, Hyderabad, Telangana 500 034, India (Name, telephone, e-mail and/or facsimile number and address of company contact person) Securities registered or to be registered pursuant to Section 12(b) of the Act. Title of Each Class Name of Each Exchange on which Registered American depositary shares, each New York Stock Exchange representing one equity share Equity Shares* * Not for trading, but only in connection with the registration of American depositary shares, pursuant to the requirements of the Securities and Exchange Commission.
    [Show full text]
  • Compendial Approvals for USP40-NF35
    Compendial Approvals for USP40-NF35 Category Monograph Title Monograph Section Scientific Liaison New <89.1> COLLAGENASE I PF 41(5) Pg. ONLINE Introduction, DEFINITION/Introduction, IDENTIFICATION/A., Edith Chang IDENTIFICATION/B., ASSAY/Procedure, PURITY/Procedure, IMPURITIES/Clostripain Activity/Potassium phosphate buffer, IMPURITIES/Clostripain Activity/Dithiothreitol solution, IMPURITIES/Clostripain Activity/Calcium chloride solution, IMPURITIES/Clostripain Activity/Substrate stock solution, IMPURITIES/Clostripain Activity/Substrate solution, IMPURITIES/Clostripain Activity/Sample solution, IMPURITIES/Clostripain Activity/Instrumental conditions, IMPURITIES/Clostripain Activity/Analysis, IMPURITIES/Clostripain Activity/System suitability, IMPURITIES/Clostripain Activity/Acceptance criteria, IMPURITIES/Trypsin Activity/Buffer, IMPURITIES/Trypsin Activity/Substrate stock solution, IMPURITIES/Trypsin Activity/Substrate solution, IMPURITIES/Trypsin Activity/Sample solution, IMPURITIES/Trypsin Activity/Instrumental conditions, IMPURITIES/Trypsin Activity/Analysis, IMPURITIES/Trypsin Activity/System suitability, IMPURITIES/Trypsin Activity/Acceptance criteria, SPECIFIC TESTS/Protein Content, SPECIFIC TESTS/Bacterial Endotoxins Test <85>, SPECIFIC TESTS/Microbial Enumeration Tests <61>, ADDITIONAL REQUIREMENTS/Packaging and Storage, ADDITIONAL REQUIREMENTS/Labeling, ADDITIONAL REQUIREMENTS/USP Reference Standards <11> New <89.2> COLLAGENASE II PF 41(5) Pg. ONLINE Introduction, DEFINITION/Introduction, IDENTIFICATION/A., Edith Chang IDENTIFICATION/B.,
    [Show full text]
  • Oxford® Policy Update Bulletin: June 2016
    June 2016 policy update bulletin Medical & Administrative Policy Updates UnitedHealthcare respects the expertise of the physicians, health care professionals, and their staff who participate in our network. Our goal is to support you and your patients in making the most informed decisions regarding the choice of quality and cost-effective care, and to support practice staff with a simple and predictable administrative experience. The Policy Update Bulletin was developed to share important information regarding Oxford® Medical and Administrative Policy updates.* *Where information in this bulletin conflicts with applicable state and/or federal law, Oxford® follows such applicable federal and/or state law Oxford® Medical and Administrative Policy Updates Overview This bulletin provides complete details on Oxford® Medical and Policy Update Classifications Administrative Policy updates. The appearance of a service or New procedure in this bulletin indicates only that Oxford® has recently New clinical coverage criteria and/or documentation review requirements adopted a new policy and/or updated, revised, replaced or have been adopted for a service, procedure, test, or device retired an existing policy; it does not imply that Oxford® provides Updated coverage for the service or procedure. In the event of an An existing policy has been reviewed and changes have not been made inconsistency or conflict between the information provided in this to the clinical coverage criteria or documentation review requirements; bulletin and the posted policy, the provisions of the posted policy however, items such as the clinical evidence, FDA information, and/or will prevail. Note that most benefit plan documents exclude from list(s) of applicable codes may have been updated benefit coverage health services identified as investigational or unproven/not medically necessary.
    [Show full text]
  • Keeping Families Safe Around Medicine March 2014 of Every Day, a Poison Control Center Answers a Call Every Minute About a Young Child Getting Into Medicine
    Keeping Families Safe Around Medicine March 2014 of every day, a poison control center answers a call Every minute about a young child getting into medicine. Nearly 500,000 calls per year. In 2012, more than 64 ,000 kids were treated in an That’s one child every 8 minutes. emergency room for medicine poisoning. Whose medicine are they getting into? 77% In 3 out of 4 of these cases, the medicine belonged to a parent or grandparent. 39% + 38% parents grand- parents The “typical” household is changing Older adults are taking with more grandparents in the home. more medicine. Older adults make up 13% of the population 23% increase 34% in the number of grand- but account for 34% of 13% parents living with their prescription medicine use. grandchildren since 2005. 74% of grandparents 1 in 8 say they take a prescription grandparents provide care on a regular medicine every day. basis for a grandchild. So kids are around more medicine than ever before. Where are grandparents storing medicine that kids might get into? Among those who use easy-open containers, 42% keep prescrip- 12% 28% tion medicine of grandparents who take keep their medicines in on a bathroom care of their grandkids every easy-open containers or kitchen sink, day keep prescription medicine or bottles without a counter, table on a nightstand or dresser. child-resistant cap. or shelf. What are they worried about? More grandparents But 3 6 times identified electrical more children go to outlets than medicine the ER for medicine as a top safety issue.
    [Show full text]
  • Pharmacists' Pharmacopeia
    3 Pharmacists’ Pharmacopeia Official May 1, 2009 – August 1, 2009 USP Pharmacists’ Pharmacopeia Notice and Warning Concerning U.S. Patent or Trademark Rights The inclusion in the USP Pharmacists’ Pharmacopeia of a monograph on any drug in respect to which pat- ent or trademark rights may exist shall not be deemed, and is not intended as, a grant of, or authority to exercise, any right or privilege protected by such patent or trademark. All such rights and privileges are vested in the patent or trademark owner, and no other person may exercise the same without express per- mission, authority, or license secured from such patent or trademark owner. Concerning Use of the USP Pharmacists’ Pharmacopeia Text Use of the USP Pharmacists’ Pharmacopeia is subject to the terms and conditions of the USP Pharmacists’ Pharmacopeia License Agreement. Attention is called to the fact that USP Pharmacists’ Pharmacopeia text is fully copyrighted. Authors and others wishing to use portions of the text should request permission to do so from the Legal Department of the United States Pharmacopeial Convention. Copyright © 2009 The United States Pharmacopeial Convention ISSN: 1930-2908 ISSN online: 1930-2916 © 2009 USP 12601 Twinbrook Parkway, Rockville, MD 20852 All rights reserved. S3/ii USP Pharmacists’ Pharmacopeia Contents USP Pharmacists’ Pharmacopeia Section 1— Section 8— Mission and Preface . S3/1 Dietary Supplement Monographs and General Chapters . S3/72 Section 2— General Notices and Requirements . S3/9 Section 13— Reference Tables of USP–NF . S3/76 Section 3— Drug Substance and Compounded Preparation Index . S3/130 Monographs . S3/22 Section 7— Pharmacy-Related General Chapters .
    [Show full text]
  • Neurodegeneration Product Guide | Edition 2
    Neurodegeneration Product Guide | Edition 2 Passion Flower Passiflora caerulea A source of Harmane Contents by Research Area: • Neurodegeneration • Alzheimer’s Disease • Parkinson’s Disease • Huntington’s Disease Tocris Product Guide Series Neurodegeneration Research Contents Page Neurodegeneration 3 Alzheimer’s Disease 5 Parkinson’s Disease 12 Huntington’s Disease 17 List of Acronyms 23 Neurodegeneration Research Products 24 Further Reading 34 Introduction Neurodegenerative diseases are highly prevalent disorders for which the greatest risk factor is increasing age. The pathogenesis of these disorders is yet to be fully understood, and current research efforts are focused on elucidating the cellular and molecular mechanisms responsible, with the hope that drugs that prevent or reverse disease progres- sion will be discovered. Three of the major neurodegenerative diseases are Alzheimer’s disease, Parkinson’s disease and Huntington’s disease, which are discussed in this product guide. Research into these disorders has so far yielded few drugs that have proven effective in clinical trials, and many current therapies are targeted at attenuating disease symptoms, rather than disease progression. Due to the prevalence of neurodegenerative diseases, they constitute a significant human, societal and economic burden. The global financial cost far outweighs other disorders such as stroke, musculoskeletal disease, heart disease or cancer. Given the aging population, the incidence of neurodegenerative disorders is predicted to rise; early diagnosis and effec- tive treatment is of paramount importance, and these rely on a greater understanding of the mechanisms that underlie each disorder. Included in this guide are key compounds used in the study of Alzheimer’s, Parkinson’s and Huntington’s disease, as well as illustrative schematics of the molecular mechanisms thought to contribute to each disease.
    [Show full text]
  • WO 2013/163455 A2 31 October 2013 (31.10.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2013/163455 A2 31 October 2013 (31.10.2013) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/415 (2006.01) A61K 31/395 (2006.01) kind of national protection available): AE, AG, AL, AM, A61P 25/00 (2006.01) C12Q 1/68 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) Number: International Application DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US20 13/038260 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 25 April 2013 (25.04.2013) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, (25) Filing Language: English RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, (26) Publication Language: English TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/638,043 25 April 2012 (25.04.2012) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: THE REGENTS OF THE UNIVERSITY GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, OF CALIFORNIA [US/US]; Office Of The President, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 111 Franklin Street, 5th Floor, Oakland, CA 94607-5200 TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (US).
    [Show full text]
  • Modeling the Binding of Inhibitors/Drugs to the Human Serotonin Transporter Kalyan Immadisetty
    Duquesne University Duquesne Scholarship Collection Electronic Theses and Dissertations Spring 2015 Modeling the Binding of Inhibitors/Drugs to the Human Serotonin Transporter Kalyan Immadisetty Follow this and additional works at: https://dsc.duq.edu/etd Recommended Citation Immadisetty, K. (2015). Modeling the Binding of Inhibitors/Drugs to the Human Serotonin Transporter (Doctoral dissertation, Duquesne University). Retrieved from https://dsc.duq.edu/etd/678 This Immediate Access is brought to you for free and open access by Duquesne Scholarship Collection. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of Duquesne Scholarship Collection. For more information, please contact [email protected]. MODELING THE BINDING OF INHIBITORS/DRUGS TO THE HUMAN SEROTONIN TRANSPORTER A Dissertation Submitted to the Bayer School of Natural and Environmental Sciences Duquesne University In partial fulfillment of the requirements for the degree of Doctor of Philosophy By Kalyan Immadisetty May 2015 Copyright by Kalyan Immadisetty 2015 MODELING THE BINDING OF INHIBITORS/DRUGS TO THE SEROTONIN TRANSPORTER By Kalyan Immadisetty Approved April 8, and 2015 ________________________________ ________________________________ Jeffry D. Madura, Ph.D. Jeffrey D. Evanseck, Ph.D. Professor of Chemistry and Biochemistry Professor of Chemistry and Biochemistry (Committee Chair) (Committee Member) ________________________________ ________________________________ David W. Seybert, Ph.D. Christopher K. Surratt, Ph.D.
    [Show full text]
  • Identifying and Controlling Poisons of the Nervous System
    Neurotoxicity: Identifying and Controlling Poisons of the Nervous System April 1990 OTA-BA-436 NTIS order #PB90-252511 Recommended Citation: U.S. Congress, Office of Technology Assessment, Neurotoxicity: Identifying and Controlling Poisons of the Nervous System, OTA-BA-436 (Washington, DC: U.S. Government Printing Office, April 1990). For sale by the Superintendent of Documents U.S. Government Printing Office, Washington, DC 20402-9325 (order form can be found in the back of this report) . Foreword Extraordinary developments in the neuroscience in recent years have been paralleled by a growing congressional interest in their policy implications. The designation of the 1990s by the 101st Congress as the “Decade of the Brain” is one indication of the promise shown by scientific advances for treating diseases of the nervous system and for increased general understanding of the human mind. Other advances, however, have led us to the disturbing realization that many commonly used chemicals can adversely affect the human nervous system. Concern about this issue provided the motivation for hearings held in October 1985 on ‘‘Neurotoxins in the Home and in the Workplace’ by the Subcommittee on Investigations and Oversight of the House Committee on Science and Technology. Another result of heightened congressional interest was a request that OTA undertake a series of assessments on major public policy issues related to the neuroscience. Requesting committees included the House Committees on Science, Space, and Technology; Energy and Commerce; Appropriations; and Veterans’ Affairs; and the Senate Subcommittee on Science, Technology, and Space of the Committee on Commerce, Science, and Transportation. In addition, the Senate Committee on Environment and Public Works recently requested a study of the noncancer health risks posed by toxic substances.
    [Show full text]
  • Nclassified United States Internationaldevelopment
    NCLASSIFIED UNITED STATES INTERNATIONALDEVELOPMENT COOPERATION AGENCY AGENCY FOR INTERNATIONAL DEVELOPMENT Washington, D. C. 20523 GRENADA PROJECT PAPER RELIEF AND RECONSTRUCTION (and Amendment # 1) kj AID/LAC/P-234 Project Number:543-0010 UNCLASSIFIED AGENCY FOR INTERNAT'ONAL tUCVLOpMENT ITRANSACT.A.dm O CODE ,I ' ' E PROJECT DATA SHEET AC-Cag COUNTRY ",,TY"' GRENADA I 3..PROJECTPO43-0010 . B,.lE R" BURE.':R. P ,5. PROJECTTIrLE *.-,amu,. 0 .hn:ct,. Latin ''rican and the Caribbean. 5L J9L]enada Mental Health Serviu:' :i.ct c, 6. PROJECT .\SI .:CE COMPLETION DATE (PACD) 7. ESTLMATED DATE O F OBLI GAIION (Under 'B'below, enter 1. 2. J, or 4) N5M1 DD YY l 310 8161 A.initiaFYLjJ HQatL C. Final r L8 L9j 8,CO5T, (1000 OR EQUIVALENT 51 = A. FUNDING SOURCE FIRST FY f5 LIFE OF PROJ ECr_... B. FX C. L/C D. Total E. FX AMD App~ropriated Total F. L/C G. T t-d 790 10 son 2,2 62 1,000 -_ 3, 2.6 (Grant) ESF ( 790 ) goo(0 2,262 1 ,(000 13 2 62 (Loan) ( ) ( )( ) ( ) _ _ _ __, Other , U.5- 2. Host Counuy LWn__n 784 8_ Other Donor(s) _ _ _ _ TOTAL S _ 790 430 1,220 2 21,74 4,046. 9. SCHEDULE OF AID FUNDING (SOOO) -P.LPRB. B.A R C. PRDARY ­ E A. APPRO. PRIMARY TECH. CODE D. OBLIG,%rIONs 0oDArE E. AMOUNT APPROVED F. LIFE OF PROJECT PRO PU.AT .. ... THIS ACTION CODE 1.Grant 2. Loan I. Grant 2. Loan 1. Grant 2.
    [Show full text]